anti-GP120/CD4 or CCR5 bispecific antibodies (Rockefeller University)

N/A

Report date: 2025/03/14 20:00:48

Base Information

Drug Nameanti-GP120/CD4 or CCR5 bispecific antibodies (Rockefeller University)

Drug Alias NameN/A

ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Multispecific monoclonal antibody > Bispecific monoclonal antibody

Mechanisms of ActionHIV envelope protein gp120 inhibitorsC-C chemokine receptor type 5 antagonistsT-cell surface antigen CD4 inhibitors

TargetsT-cell surface antigen CD4C-C chemokine receptor type 5HIV envelope protein gp120

Therapy Area/IndicationsHIV Infections

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryUnited States

CombinationsNo

Global Highest StatusPending (Preclinical)

Highest Status in ChinaN/A

Originator CompaniesThe Rockefeller University

China Registration ClassN/A

Develop Information

Active CompaniesN/A

Inactive CompaniesThe Rockefeller University

Active IndicationsN/A

Inactive IndicationsHIV Infections

Other Information

ATC CodeN/A